Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (September 2025)
40 slides from Preveceutical Medical's investor presentation, Sep 1, 2025
Slide 1: Investor Presentation
Pr eveC eu tic al Med ic a l I nc . C SE :PRE V | OTC : PRVC F | FS E: 18H Q3 - 2025 Investor Presentation biogenetherapeutics. com 1
Slide 2: Our Mission
Our Mission BioGene commits to Delivering the Future of Genetic Medicines with Precision Delivery, opening the door to alternative patient-friendly routes of LNP administration through innovative products and platforms that target key tissues of interest in obesity and diabetes…and beyond! biogeneth
Slide 3: Our Vision
Our Vision Our vision is to deliver safe, effective, patient -friendly curative therapies for metabolic disorders that restore normal metabolic function involved in glucose regulation and fat metabolism. biogenetherapeutics. com 3 32 2
Slide 4: Board of Directors
Board of Directors Stephen Van Deventer Deepak Sampath, PhD Steve Glover Patroski J. Lawson, MSP Stephen is the Deepak will serve as Steve joins BioGene as Linnéa has been Chairman, CEO and an Independent a Board Member, appointed Director of President of BioGene Director for BioGene. bringing multi
Slide 5: Senior Management
Senior Management Stephen Van Deventer Alex McAuly, CPA Harry Parekh, PhD Francis Tavares, PhD Kamal Albarazanji Stephen is the Alex serves as the Harry is welcomed to Stephen is the Kamal joins BioGene Chairman, CEO and Chief Financial the BioGene team as Chairman, CEO and Therapeutics as the Presi
Slide 6: Scientific and Corporate Advisory Board
Scientific and Corporate Advisory Board Prof. Mirela Delibegović Barry Ticho, MD, PhD Mariya Georgieva, PhD Brian Gallagher, Jr. Kathy Rokita As a member of Barry will serve on Mariya will serve on Brian will sit on the Kathy is joining the BioGene’s Scientific BioGene’s Scientific BioGene’s Scienti
Slide 7: BioGene Australia
BIOGENE AUSTRALIA BioGene has established a wholly-owned subsidiary in Brisbane, Queensland, Australia. Bolster R&D activities and provide significant R&D Formulation & Preclinical Facility cash-back on R&D from the Australian government. Brisbane BioGene is eligible to receive 43.5% cash back from
Slide 8: Problem
Problem OBESITY 1 Cases have tripled in the past decade leading to elevated risk of mortality: heart disease, stroke and dementia. DIABETES 2 1 in 10 adults are diagnosed with diabetes. Childhood rates of diabetes & obesity are on a steep upward trajectory. DRUG SIDE EFFECTS 3 Debilitating and even
Slide 9: Obesity Rates and Diabetes Rates
Obesity Rates Diabetes rates 1 -in-10 Adults are Diabetic with Obesity Cases Triple in a Decade Child Cases Rapidly Rising • The World Obesity Federation (WOF) predicts • Leads to >4 million adult deaths a year. the economic impact of obesity will reach >US$4 trillion annually by 2035. • Over 570 mi
Slide 10: GLP1 agonists changed the paradigm but unmet needs remain
GLP1 agonist have changed the obesity treatment paradigm but significant unmet medical needs remain Present with an array of issues: • Severe sometimes life-threatening side effects Muscle Loss Is • 40% of patients stop treatment by one year Significant • 20-40% muscle loss • Patients build toleranc
Slide 11: The Obesity Landscape is Evolving into Next-Generation Therapies
The Obesity Landscape is Rapidly Evolving into NextGeneration Therapies biogenetherapeutics. com 11
Slide 12: Landscape of Nucleic Acid Therapeutics for Obesity Treatment
Landscape of Nucleic Acid Therapeutics for Obesity Treatment siRNA Companies Alnylam Pharmaceuticals (NASDAQ: ALNY) •Program: ALN-APP (targeting amyloid precursor protein in the CNS) and other metabolic disease candidates •Technology: Proprietary siRNA platform, with success in multiple therapeutic
Slide 13: BioGene's A-to-Z solution
BioGene’s A-to-Z solution Dual gene therapy siRNAs targeting obesity and diabetes -> restore metabolic function with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNA's PLATFORM LNP PLATFORM THERAPY Bioresponsive self- Metabolically- A vers
Slide 14: SOL-GEL Nose-To-Brain Platform Delivery
SOL-GEL Nose-To-Brain Platform Delivery Direct Nose-to-Brain Delivery Challenges with Oral The Blood-Brain-Barrier Olfactory Pathway Delivery Route Targeting with Sol-Gel Desired patient outcomes are BBB remains a universal achieved by consistent and Rapid breakdown by hurdle for drugs intended for
Slide 15: What is the Sol-Gel Platform?
What is the Sol-Gel Platform? A solution that is engineered to rapidly gel upon contact with mucosa… • Targeted spray delivery and retention on mucosa • Controlled and sustained release (nanomicellar-formulation) to and through mucosa Room temperature Body Temperature temperature Solution state perm
Slide 16: Conventional nasal spray delivery intranasally
Conventional nasal spray delivery intranasally Nasal sprays deliver formulation throughout the nasal cavity, and are rapidly cleared… • Anterior & posterior leakage • Rapid ciliary clearance • Poor retention • Unpredictable transmucosal delivery to trigeminal nerves biogenetherapeutics. com 16
Slide 17: Sol-Gel Platform Technology & Device
Sol-Gel Platform Technology & Device Olfactory mucosa targeting, rapid sol-to-gel transition, muco-retention and sustained delivery • Exclusive olfactory targeting • Direct, rapid nose-to-brain delivery • Mucoadhesive sol-gel provides for sustained & controlled delivery • Patient-friendly water or b
Slide 18: PoC study using N2B sol-gel for treatment refractive psychosis
PoC study using N2B sol-gel for treatment refractive psychosis… Clozapine: Clozapine: Peripheral The ‘Gold Side Standard’ EffectsAnti-Psychotic Drug (APD) ACTIONS WORST SIDE EFFECTS ↓ Suicidality Myocarditis / Cardiomyopathy ↓ Hallucinations & delusions Metabolic Syndrome ↓ Risk of EPS OBESITY T2DM
Slide 19: PoC study confirms N2B sol-gel brain-biased delivery
PoC study confirms N2B sol-gel brain-biased delivery for treatment refractive psychosis… • Clozapine is exemplary in alleviating positive & negative ve symptoms of psychosis, but is plagued with serious, debilitating peripheral side effects, limiting it’s use to treatment refractive schizophrenia •
Slide 20: PoC study confirms N2B sol-gel is efficacious
PoC study confirms N2B sol-gel is efficacious for treatment refractive psychosis… Clozapine anti-psychotic drug action - daily dosing for 7 days (acute study) Acute Oral Acute Intranasal 100 100 80 80 % CAR 60 60 This is 28-fold 40 Control 40 Control lower than Clozapine Clozapine the oral 20 20 dos
Slide 21: BioGene's Solution for Next Generation Diabetes and Obesity Therapeutics
BioGene’s Solution for Next Generation Diabetes and Obesity Therapeutics Dual gene therapy siRNAs targeting obesity and diabetes -> restore metabolic function with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNA's PLATFORM LNP PLATFORM TH
Slide 22: Non-Viral Vector Platform - Bioresponsive LNPs (bLNP)
Non-Viral Vector Platform - BioGene’s Bioresponsive LNPs (bLNP) • Next generation – non-viral bioresponsive vector • US Patent # 11,566,044 granted, 31st March 2023 Comprehensive release of all genetic cargo from their carrier… Significant implications for precision medicine in mainstream disease re
Slide 23: PTP1B Validation in Diabetes & Obesity
P T P 1B Validation in Diabetes (insulin resistance) & Obesity(leptin signaling) PTP1B directly dephopshorylates the Insulin Receptor while indirectly acting on the leptin receptor to regulate satiety through Jak2/Stat3. Dual therapy approach:our bLNPs specifically targeting PTP1B has been uniquely
Slide 24: PTP1B in the CNS only restores insulin & leptin sensitivity
PTP1B in the CNS only, restores both insulin & leptin sensitivity* PTP1B -/- in leptin-receptor expressing neurons Neuron-specific PTP1B -/- leads to leads to CNS • Decrease in body weight & fat mass • Leptin hypersensitivity • Increased activity and energy expenditure • Decrease in body weight & fa
Slide 25: Central PTP1B targeting exhibits the most profound global effects
Central (brain) PTP1B targeting exhibits the most profound global effects on both energy balance & glucose homeostasis* • Global neuronal deletion of PTP1B dramatically reduces obesity and enhances leptin + insulin sensitivity % • Various areas of the brain involved in energy balance (hypothalamus,
Slide 26: Targeting PTP1B in peripheral tissue vs CNS
Targeting PTP1B in peripheral tissue vs CNS – key differences Studies correlating lowered PTP1B levels to metabolic impact in liver, muscle and adipose tissue highlight: For the Periphery • In liver – this improves insulin signalling & responsiveness, reduces gluconeogenesis & lipogenesis, alleviate
Slide 27: Mice lacking neuronal PTP1B are resistant to diet-induced obesity
Mice lacking neuronal PTP 1 B are resistant to diet-induced obesity and are protected from developing leptin resistance WT WT PTP1B+ /- PTP1B+ /- PTP1B- / - PTP1B- / - WT PTP1B- / - WT PTP1B- / - Conclusion of the study: “for effective obesity treatment and optimal therapy for type 2 diabetes, PTP1B
Slide 28: PoC for PTP1B Targeting In Vivo: antisense in diabetic mice
PoC for PTP1B Targeting In Vivo: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice Zinker B, Rondinone CM et al. PNAS, August 2002, 99(17): 11357-11362 IV Delivery biogenetherapeutics. com 28
Slide 29: PoC for PTP1B Targeting In Vivo: antisense in monkeys
PoC for PTP1B Targeting In Vivo: Antisense oligonucleotides suppresses Protein Tyrosine Phosphatase-1B and modulates key regulators of glucose and fat metabolism in non-obese monkeys IV Delivery Swarwick M et al. Endocrinology, April 2009, 150(4):1670–1679 biogenetherapeutics. com 29
Slide 30: PoC for PTP1B Targeting In Vivo: dose-dependent insulin sensitivity
PoC for PTP1B Targeting In Vivo: Inhibition of Protein Tyrosine Phosphatase- 1B with antisense oligonucleotides improves insulin sensitivity in monkeys in a dose-dependent manner IV Delivery Insulin Resistant Rhesus Macaques Normal Non-Obese Rhesus Macaques Swarwick M et al. Endocrinology, April 200
Slide 31: Comparison of targets - GLP1RAs & PTP1B
Comparison of targets - GLP1RAs & PTP1B Mechanism of action: GLP1RAs - increase insulin secretion (pancreas), delay gastric emptying (direct GI effects) and reduce appetite (CNS) PTP1B inhibition - enhances insulin and leptin receptor signalling in brain, liver, muscle & adipose tissue, targeting th
Slide 32: PTP1B: Obesity, T2D and Beyond
PTP1B : Obesity, T2D AND BEYOND! PTP1B inhibition reduces neuroinflammation and fronto-temporal dementia in animal models displaying potential for the treatment of Alzheimer’s Disease Source: Pharmacological PTP1B inhibition rescues motor learning, neuroinflammation, and hyperglycaemia in a mouse mo
Slide 33: Gene Targeting Strategy with Smart-siRNAs against PTPN1
Gene Targeting Strategy with BioGene’s ‘Smart-siRNAs’ against the PTPN1 gene The PTPN1 gene comprises 10 exons, each potential targets for siRNA: 1 2 3 4 5 6 7 8 9 10 63bp 91bp 101bp 99bp 138bp 210bp 162bp 224bp 196bp 24bp 01 02 03 Successfully engineered siRNA’s against both siRNA sequences were se
Slide 34: Potent Gene Silencing Confirmed with bLNPs
Potent Gene Silencing Confirmed bLNP-1 withBioGene’s BioresponsiveLNPs (bLNPs) • bLNPs possess the unique bioresponsive ‘gene- releasing’ linker (US Patent #11,566,044 – granted 31/Mar/23). • UQP12 & UQP15 (top and bottom graphs) represent select bLNP-2 Smart-siRNAs showing potent gene silencing whe
Slide 35: Planned Diabetes and Obesity Preclinical Study
Planned Diabetes and Location: The University of Queensland, Brisbane 01 • Extensive expertise with Sol-Gel engineering, bLNP Obesity formulation & preclinical models of obesity and diabetes Preclinical Study Research Team Led by BioGene’s Chief Scientific 02 Officer & Co-Founder, Dr. Harry Parekh.
Slide 36: Key Milestones: Path to IND and Phase 1
Key Milestones: Path to IND and Phase 1 2025 2026 2027 Q2-Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Vector & formulation cGMP DP Package & Drug Release Stability Initiation CMC In vivo proof-of-concept (PoC) sol-gel N2B delivery & biodistribution study in wild-type non-obese mice after a single administration In v
Slide 37: Key Activities, Inflection Points and Regulatory Milestones
Key Activities, Inflection Points and Regulatory Milestones Next 18 months • Initiate and complete obesity/diabetes animal model studies • Initiate GLP toxicology studies • Manufacture clinical supplies • File IND and begin phase I trials Development IND Status and Target Program Key Activities Key
Slide 38: Revenue and Corporate Strategy
Revenueand CorporateStrategy Platform Acquisition and Direct Listing Licensing Partnerships on NASDAQ Potential biogenetherapeut ics. com biogenetherapeutics. com 38
Slide 39: Global Collaborators
Global Collaborators biogenetherapeut ics. com 39
Slide 40: Thank you
Thank you biogenetherapeutics. com 40
PreveCeutical Medical — Investor Presentation (September 2025) on 6ix